JPH0476965B2 - - Google Patents
Info
- Publication number
- JPH0476965B2 JPH0476965B2 JP61154093A JP15409386A JPH0476965B2 JP H0476965 B2 JPH0476965 B2 JP H0476965B2 JP 61154093 A JP61154093 A JP 61154093A JP 15409386 A JP15409386 A JP 15409386A JP H0476965 B2 JPH0476965 B2 JP H0476965B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- pulmonary surfactant
- surfactant
- freezing
- frozen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000007710 freezing Methods 0.000 claims description 36
- 230000008014 freezing Effects 0.000 claims description 36
- 239000003580 lung surfactant Substances 0.000 claims description 35
- 239000004094 surface-active agent Substances 0.000 claims description 28
- 239000000725 suspension Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 25
- 150000003904 phospholipids Chemical class 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 description 28
- 238000009472 formulation Methods 0.000 description 21
- 239000006185 dispersion Substances 0.000 description 20
- 239000002245 particle Substances 0.000 description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 230000007935 neutral effect Effects 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 229960001231 choline Drugs 0.000 description 5
- -1 choline phosphoglyceride Chemical class 0.000 description 5
- 229940066294 lung surfactant Drugs 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000596 artificial lung surfactant Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61154093A JPS6310718A (ja) | 1986-07-02 | 1986-07-02 | 肺表面活性物質製剤の製造法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61154093A JPS6310718A (ja) | 1986-07-02 | 1986-07-02 | 肺表面活性物質製剤の製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6310718A JPS6310718A (ja) | 1988-01-18 |
| JPH0476965B2 true JPH0476965B2 (fr) | 1992-12-07 |
Family
ID=15576752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61154093A Granted JPS6310718A (ja) | 1986-07-02 | 1986-07-02 | 肺表面活性物質製剤の製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6310718A (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0521398T3 (da) * | 1991-07-05 | 1999-07-05 | Rhone Poulenc Rorer Gmbh | Phospholipidsammensætning |
| US5438044A (en) * | 1992-06-30 | 1995-08-01 | Rhone-Poulenc Rorer | Phospholipid composition |
| US6391851B1 (en) | 1997-03-10 | 2002-05-21 | Fujisawa Pharmaceutical Co., Ltd. | Hydrochlorides of vancomycin antibiotics and process for producing the same |
-
1986
- 1986-07-02 JP JP61154093A patent/JPS6310718A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6310718A (ja) | 1988-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Application of LF-NMR to the characterization of camellia oil-loaded pickering emulsion fabricated by soy protein isolate | |
| US3932943A (en) | Method of preparation of lyophilized biological products | |
| Bearer et al. | Fusion of phospholipid vesicles arrested by quick-freezing. The question of lipidic particles as intermediates in membrane fusion | |
| Segall et al. | A modified ice cream processing routine that promotes fat destabilization in the absence of added emulsifier | |
| Mangino | Protein interactions in emulsions: protein-lipid interactions | |
| HU229090B1 (en) | Improvements in or relating to contrast agents | |
| JP2008520577A (ja) | 肺表面活性物質配合物を凍結乾燥により生成する方法並びにその配合物及び利用 | |
| NO180363B (no) | Beskyttelsesmiddelblandinger for stabilisering av liposomer under törking | |
| KR102350284B1 (ko) | 초음파 전구체 제조 방법 | |
| KR19990082670A (ko) | 열 안정화된 조영제 | |
| CZ20012328A3 (cs) | Emulze | |
| WO1997035882A1 (fr) | Compositions lyophilisees de peptides tensioactifs pulmonaires | |
| Vincent et al. | Surface activity of yolk, plasma and dispersions of yolk fractions | |
| KR102556398B1 (ko) | 기체-충전 미세소포를 위한 동결-건조 제제 | |
| Lu et al. | The effect of dextran to restore the activity of pulmonary surfactant inhibited by albumin | |
| JPH0476965B2 (fr) | ||
| PL173024B1 (pl) | Sposób wytwarzania napowietrzanych słodyczy mrożonych | |
| JP2601749B2 (ja) | 起泡性水中油形食用油脂組成物及び同組成物を用いたケーキ製造法 | |
| JPS59113857A (ja) | ホイツプデザ−トの製造法 | |
| US2619423A (en) | Powdered topping and method of making the same | |
| JP3103582B2 (ja) | 低粘度、高濃度サーファクタント懸濁液 | |
| Moschetta et al. | Incorporation of cholesterol in sphingomyelin-phosphatidylcholine vesicles has profound effects on detergent-induced phase transitions | |
| McCabe et al. | The dispersion of cholesterol with phospholipids and glycolipids | |
| Sato et al. | Hydrolysis of mixed lipid emulsions containing medium‐chain and long‐chain triacylglycerol with lipoprotein lipase in plasma‐like medium | |
| JPH03181415A (ja) | リポソーム表面の修飾方法および修飾装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |